Phase II study of single fraction HDR combined with whole pelvic IMRT for prostate cancer

Phase II study of single fraction HDR combined with whole pelvic IMRT for prostate cancer - Phase II study of single fraction HDR combined with whole pelvic IMRT for prostate cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021645

Enrollment

Registered

2016-03-27

Start date

2016-02-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

Radiation therapy(High dose rate intersitial brachytherapy 15 Gy*1fraction+External beam radiation)

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1.Prostate cancer 2.High risk 3.PS 0-1

Exclusion criteria

Exclusion criteria: 1.Synchronous malignancies 2.Past medical history of pelvic radiotherapy 3.Past medical history of surgery, HIFU, and chemotherapy for prostate cancer 4.Inflammatory bowel disease such as Crohn disease or ulcerative colitis

Design outcomes

Primary

Measure	Time frame
The rate of chronic adverse events	—

Secondary

Measure	Time frame
5 year PSA relapse free survival, 5 year clinical relapse free survival, 5 year overall survival, the rate of acute adverse events	—

Countries

Japan

Contacts

Public ContactKoji Inaba

National Cancer Center Hospital, Japan Department of Radiation Oncology

koinaba@ncc.go.jp03-3542-2511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026